EAN 2023: Eighty Percent of Patients Revert From Chronic to Episodic Migraine by 48 Weeks With Anti-CGRP Monoclonal Antibodies
Real-life data demonstrate higher efficacy than that reported in randomized controlled trials
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.